One of the small molecule drug classes that has caught my attention is the BET-Bromodomain inhibitors.
Have a look at some of the work that Dana Farber are doing with MYC & BET-Bromodomain inhibitors, then have a read of page 4 of Phylogica's February 2015 Newsletter under the heading 'Competitive landscape' and page 15 of the 2015 Annual General Meeting announcement below.
Phylogica references:
http://phylogica.com/media/articles...50217-Shareholder-Newsletter-1307/1410832.pdf (Newsletter)
http://www.asx.com.au/asxpdf/20151125/pdf/4338wdv3rl385c.pdf (2015 Annual General Meeting)
Dana Farber references:
http://www.dana-farber.org/Newsroom...irst-success-against-elusive-cancer-gene.aspx
http://www.dana-farber.org/Newsroom/Publications/Crowd-Sourcing.aspx
http://www.dana-farber.org/Newsroom...cancer-dependencies-in-lymph-node-cancer.aspx
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $734.9M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |